Description: Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
Home Page: www.crossject.com
6 Rue Pauline Kergomard
Dijon,
21000
France
Phone:
33 3 80 54 98 50
Officers
| Name | Title |
|---|---|
| Mr. Patrick Alexandre | Co-Founder, CEO & Chairman of the Executive Board |
| Dr. Isabelle Liebschütz | Chief Quality & Regulatory Officer and Member of Executive Board |
| Mr. Olivier Giré | COO of Specialty Pharma & Member of Executive Board |
| Dr. Dan Chiche M.D. | Chief Medical Officer North America |
| Mr. Tony Tipton | Chief Operating Officer of U.S |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 41.3118 |
| Price-to-Sales TTM: | 31.4684 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 105 |